<DOC>
	<DOCNO>NCT00946647</DOCNO>
	<brief_summary>The purpose randomize , two-arm , open-label expansion phase study collect preliminary efficacy data panobinostat recommend phase II dose ( RPIID ) level combination azacytidine ( 5-Aza ) versus active control arm 5-Aza alone . This randomized phase II part allow also collect safety data panobinostat combination 5-Aza comparison single-agent 5-aza .</brief_summary>
	<brief_title>A Phase Ib/IIb , Open-label , Multi-center , Study Oral Panobinostat Administered With 5-Azacitidine ( Adult Patients With Myelodysplastic Syndromes ( MDS ) , Chronic Myelomonocytic Leukemia ( CMML ) , Acute Myeloid Leukemia ( AML ) .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Phase l : Patients cytopathologically confirm diagnosis AML accord WHO criterion , exclude acute promyelocytic leukemia eligible Vidaza treatment ECOG performance status great less equal 2 Phase : Adult patient ( age ≥ 18 year ) candidate treatment 5Aza present one following : intermediate2 highrisk myelodysplastic syndrome accord International Prognostic Scoring System ( IPSS ) . OR AML multilineage dysplasia maximum 30 % blast ( former RAEBT accord FAB ) OR chronic myelomonocytic leukemia ( CMML ) Patients must follow laboratory value unless elevation consider due MDS leukemia : AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN ; serum creatinine ≤ 1.5 x ULN ; serum bilirubin ( total direct ) ≤ 2 x ULN ; electrolyte panel within normal range ( WNL ) institution . Phase l : Prior treatment deacetylase inhibitor Concurrent therapy investigational agent Phase : Planned hematopoietic stemcell transplantation ( HSCT ) Patients therapyrelated MDS Patients therapyrelated AML and/or relapsed/refractory AML Patients impaired cardiac function include follow : Complete leave bundle branch block use permanent cardiac pacemaker , congenital long QT syndrome , history presence ventricular tachyarrhythmia , clinically significant rest bradycardia ( &lt; 50 beat per minute ) , QTcF &gt; 460 m screen ECG , right bundle branch block + leave anterior hemiblock ( bifascicular block ) Presence unstable atrial fibrillation ( ventricular response rate &gt; 100 bpm ) . Patients stable atrial fibrillation eligible provide meet cardiac exclusion criterion Previous history angina pectoris acute MI within 6 month Screening LVEF &lt; 45 % echocardiography MUGA Other clinically significant heart disease ( e.g . uncontrolled hypertension history poor compliance antihypertensive regimen ) . Any concurrent severe and/or uncontrolled medical condition could compromise participation study . For example : Uncontrolled diabetes Active uncontrolled infection Uncontrolled hypothyroidism Acute chronic liver renal disease Patient evidence clinically significant mucosal internal bleeding Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Chronic Myelomonocytic Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>hypomethylating therapy</keyword>
	<keyword>deacetylase inhibitor</keyword>
	<keyword>MDS</keyword>
	<keyword>CMML</keyword>
	<keyword>AML</keyword>
</DOC>